Evidence map›Paper›PMID 30328700›Full record

ArticleAIDS research and human retroviruses2019

Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.

Narayanaiah Cheedarla, Jagadish Chandrabose Sundaramurthi, Babu Hemalatha, Brahmaiah Anangi, Manohar Nesakumar, Manickam Ashokkumar, K K Vidya Vijayan, Srikanth Prasad Tripathy, Soumya Swaminathan, S Kalyanaraman Vaniambadi and 2 more

Abstract read
In one paragraph

Article in AIDS research and human retroviruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Narayanaiah Cheedarla1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Jagadish Chandrabose Sundaramurthi1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Babu Hemalatha1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Brahmaiah Anangi2 Molecular Virology Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India.
Manohar Nesakumar1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Manickam Ashokkumar1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
K K Vidya Vijayan1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Srikanth Prasad Tripathy1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Soumya Swaminathan1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
S Kalyanaraman Vaniambadi3 Advanced Bioscience Laboratories, Inc., Rockville, Maryland.
D Vadakkupattu Ramanathan1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Luke Elizabeth Hanna1 Department of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several broadly neutralizing antibodies (bNAbs) that can target HIV strains with large degrees of variability have recently been identified. However, efforts to induce synthesis of such bNAbs that can protect against HIV infection have not met with much success. Identification of specific epitopes encoded in the HIV-1 envelope (Env) that can direct the host to synthesize bNAbs remains a challenge. In a previous study, we identified 12 antiretroviral therapy-naive HIV-1-infected individuals whose plasma exhibited broad cross-clade neutralization property against different clades of HIV-1. In this study, we sequenced the full-length HIV-1 gp160 from 11 of these individuals and analyzed the sequences to identify bNAb epitopes. We identified critical residues in the viral envelopes that contribute to the formation of conformational epitopes and possibly induce the production of bNAbs, using in silico methods. We found that many of the sequences had conserved glycans at positions N160 (10/11) and N332 (9/11), which are known to be critical for the binding of PG9/PG16-like and PGT128-like bNAbs, respectively. We also observed conservation of critical glycans at positions N234 and N276 critical for the interaction with CD4 binding site bNAbs in 8/11 and 11/11 sequences, respectively. We modeled the three-dimensional structure of the 11 HIV-1 envelopes and found that though each had structural differences, the critical residues were mostly present on the surface of the Env structures. The identified critical residues are proposed as candidates for further evaluation as bNAb epitopes.

Indexed as

Epitope MappingAdultAntibodies, NeutralizingEpitopesFemaleHIV-1HIV AntibodiesHIV Envelope Protein gp160HIV InfectionsHumansMaleMiddle AgedSequence Analysis, DNAAntibodies, NeutralizingEpitopesHIV AntibodiesHIV Envelope Protein gp160broadly neutralizing antibodiesepitope specificityHIV-1HIV-1 Env structuresubtype C envelope

Identifiers

PMID30328700
PMCPMC6909397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.